A Phase 2a Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide Plus a Reduced Calorie Diet and Increased Physical Activity in Participants With Obesity
Latest Information Update: 28 Oct 2025
At a glance
- Drugs NT-0796 (Primary) ; Semaglutide
- Indications Obesity
- Focus Adverse reactions
- Acronyms RESOLVE-2
- Sponsors Nodthera
Most Recent Events
- 28 Oct 2025 New trial record